Wave Life Sciences (WVE) Cash from Financing Activities (2015 - 2026)

Wave Life Sciences (WVE) has 12 years of Cash from Financing Activities data on file, last reported at $330000.0 in Q2 2026.

• Quarterly Cash from Financing Activities fell 97.18% year-over-year to $330000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $475.2 million (up 86.68% YoY) and the FY2025 annual result came in at $488.2 million, up 92.3% from the prior year.
• Cash from Financing Activities retreated to $330000.0 in Q2 2026, from $2.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $439.7 million in Q4 2025 to a low of $17000.0 in Q3 2022.
• A 5-year average of $52.5 million and a median of $7.9 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 99.84% — and 2023, when it jumped 170740.0%.
• Tracing WVE's Cash from Financing Activities over 5 years: stood at $55000.0 in 2022, then jumped by 170740.0% to $94.0 million in 2023, then plunged by 62.77% to $35.0 million in 2024, then soared by 1156.95% to $439.7 million in 2025, then plunged by 99.92% to $330000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $330000.0 (Q2 2026), $2.5 million (Q1 2026), and $439.7 million (Q4 2025), per Business Quant data.